GIVLAARI Drug Patent Profile

When do Givlaari patents expire, and when can generic versions of Givlaari launch?

Givlaari is a drug marketed by Alnylam Pharms Inc and is included in one NDA. There are eight patents protecting this drug.

This drug has one hundred and eighty-five patent family members in forty-three countries.

The generic ingredient in GIVLAARI is givosiran sodium. One supplier is listed for this compound. Additional details are available on the givosiran sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Givlaari

Givlaari was eligible for patent challenges on November 20, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 20, 2026. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for GIVLAARI

International Patents:	185
US Patents:	8
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for GIVLAARI

US Patents and Regulatory Information for GIVLAARI

GIVLAARI is protected by eight US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on INDICATED FOR THE TREATMENT OF ADULTS WITH ACUTE HEPATIC PORPHYRIA (AHP).

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alnylam Pharms Inc	GIVLAARI	givosiran sodium	SOLUTION;SUBCUTANEOUS	212194-001	Nov 20, 2019		RX	Yes	Yes
Alnylam Pharms Inc	GIVLAARI	givosiran sodium	SOLUTION;SUBCUTANEOUS	212194-001	Nov 20, 2019		RX	Yes	Yes			Y	Y
Alnylam Pharms Inc	GIVLAARI	givosiran sodium	SOLUTION;SUBCUTANEOUS	212194-001	Nov 20, 2019		RX	Yes	Yes			Y	Y
Alnylam Pharms Inc	GIVLAARI	givosiran sodium	SOLUTION;SUBCUTANEOUS	212194-001	Nov 20, 2019		RX	Yes	Yes			Y	Y

International Patents for GIVLAARI

When does loss-of-exclusivity occur for GIVLAARI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Eurasian Patent Organization

European Patent Office

Guatemala

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Morocco

Netherlands

New Zealand

Norway

Peru

Philippines

Poland

Portugal

San Marino

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering GIVLAARI around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	097920
Argentina	118658
Argentina	133772
Australia	2014331604

Supplementary Protection Certificates for GIVLAARI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3052628	132020000000106	Italy		PRODUCT NAME: GIVOSIRAN O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(GIVLAARI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1428, 20200304
3052628	122020000045	Germany		PRODUCT NAME: GIVOSIRAN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/20/1428 20200302
3052628	LUC00175	Luxembourg		PRODUCT NAME: GIVOSIRAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/20/1428 20200304
3052628	C202030043	Spain		PRODUCT NAME: GIVOSIRAN O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/20/1428; DATE OF AUTHORISATION: 20200302; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1428; DATE OF FIRST AUTHORISATION IN EEA: 20200302

Last updated: July 6, 2026

GIVLAARI (givosiran) Investment Scenario and Patent-Funded Fundamentals Analysis: Exclusivity, Competitive Risk, and Revenue Outlook

Executive summary: GIVLAARI (givosiran) is a niche, high-efficacy RNAi therapy for acute hepatic porphyria (AHP). The near-to-mid term investment case is driven by (1) durability of patent and regulatory exclusivity, (2) ability to expand diagnosis and retention in AHP centers, (3) payor contracting for a high-cost drug, and (4) competitive pressure from other AHP pipeline assets and potential incremental delivery/formulation approaches. The business risk is concentrated in exclusivity and competitor timing more than in near-term manufacturing or operational constraints, given the drug’s specialty profile.

---

What is GIVLAARI (givosiran) used for and why does it matter commercially?

Answer: GIVLAARI (givosiran) is indicated to reduce the frequency of attacks in adults with acute hepatic porphyria (AHP). The commercial profile is specialty and centered on a small treated-population with high unmet need, making reimbursement and clinician adoption key determinants of revenue durability.

How does givosiran work and how does that shape payer and prescriber behavior?

• Mechanism: small interfering RNA (siRNA) that lowers hepatic ALAS1 (aminolevulinate synthase 1), reducing heme-pathway metabolites implicated in AHP attacks.
• Clinical posture: dosing convenience and attack reduction are the core value propositions in AHP centers, which influences:
  • insurer willingness to cover through prior authorization and response criteria;
  • center-level prescribing consistency after dose initiation;
  • switch dynamics versus older prophylaxis or symptom-driven regimens.

Where does revenue come from in AHP?

• Primary revenue driver: number of diagnosed and treated patients initiating and staying on therapy.
• Secondary driver: retention and dose continuity (avoiding discontinuation due to tolerability, lab monitoring burden, or reimbursement friction).

---

What is the Orange Book status of GIVLAARI and what does it imply for generic risk?

Answer: GIVLAARI is not an “Orange Book small-molecule” generics-and-REMS story because it is a biologic-like RNAi drug typically outside the standard Abbreviated New Drug Application generic framework. The investment implication is that “generic entry” risk must be evaluated through new regulatory pathways for RNAi/biologic-like products, not typical ANDA-style equivalence.

What does that mean for investor timelines?

• Generic timelines for classic chemical drugs do not map cleanly to RNAi mechanisms.
• The practical generic risk for RNAi concentrates in:
  • patent claims (composition of matter, sequence, delivery system, and manufacturing);
  • regulatory exclusivity and any data exclusivity or sponsor-specific exclusivity periods;
  • trial and analytical comparability barriers for an RNAi system.

(Patent and exclusivity specifics depend on the exact listed patents and regulatory exclusivity periods; those must be anchored to the FDA Orange Book and Orange Book listing dates to compute hard entry dates.)

---

When does GIVLAARI lose exclusivity: what are the key IP and regulatory “cliffs”?

Answer: The investment “cliff risk” is driven by patent term expiration on givosiran-related claims plus any regulatory exclusivity that blocks an alternative approval pathway for a time-limited period after the first approval.

Key exclusivity levers to model

1. Composition-of-matter patents covering:
   • givosiran nucleotide sequences or variants;
   • conjugate chemistry;
   • target engagement construct.
2. Formulation and delivery system patents covering:
   • nanoparticle or conjugate delivery architecture,
   • manufacturing method claims.
3. Regulatory exclusivity:
   • data exclusivity (and any pediatric or orphan-related extensions if applicable to the original approval basis).

What investors should watch in the schedule

• The share price sensitivity typically concentrates on:
  • the year the core composition claims expire;
  • whether later patents (formulation, manufacturing, method-of-use) extend protection;
  • any Patent Term Adjustment or Patent Term Extension events that shift expiration dates.

(Hard “date math” requires the specific listed FDA patents and their expiration dates.)

---

What patents protect GIVLAARI (givosiran) and how strong is the patent estate?

Answer: For an RNAi drug, the relevant patent estate typically clusters around sequence/composition, conjugate/delivery, manufacturing, and method-of-use. Patent strength depends on claim scope durability against design-arounds and on litigation outcomes, if any.

Patent estate architecture for RNAi drugs (what to expect)

• Sequence and composition claims: cover the siRNA strand design that targets ALAS1.
• Conjugate and delivery claims: cover the ligand chemistry used to route delivery to relevant tissues (commonly hepatocyte-targeting strategies).
• Formulation claims: cover the final dosage form stability, excipients, particle characteristics, or lyophilization parameters.
• Manufacturing method claims: cover steps for synthesis and purification, including quality control-defined intermediates.

How to evaluate “strength” for investment

• Breadth: does the claim require the exact sequence, or cover families of variants?
• Design-around feasibility: can a competitor create a non-infringing sequence or delivery architecture that retains clinical effectiveness?
• Enforcement history: litigation outcomes, settlements, or license terms signal claim durability.

(Specific patent numbers, assignees, and expiration dates must be pulled from FDA listings and published patent records to produce the “hard-data” estate map.)

---

What formulations and manufacturing patents protect givosiran (GIVLAARI)?

Answer: Manufacturing and formulation patents for RNAi drugs are typically used to prevent non-infringing production of the same final product and to limit “drop-in” substitutes that match the clinical-active construct but use different processes.

What to model in competitive scenarios

• A competitor may attempt to:
  • use the same RNA sequence but different manufacturing process,
  • keep the same delivery approach but alter formulation excipients or presentation,
  • change the delivery chemistry while preserving the same pharmacology.

If formulation or manufacturing patents are strong, those design-arounds increase development time and cost.

---

What method-of-use patents cover GIVLAARI (givosiran) and do they extend exclusivity?

Answer: Method-of-use patents can extend commercial life if they claim specific dosing regimens, patient populations, or treatment monitoring protocols that differ from general labeling.

How method claims affect generic/competitor timing

• If competitors must run studies for a different dosing regimen or different therapeutic subset to avoid infringement, that can delay approval and market entry.
• If method claims align tightly with the approved label, they become a direct barrier to “label-filling” entry strategies.

---

Which companies are developing competing therapies for acute hepatic porphyria (AHP)?

Answer: The relevant competitive set is AHP-focused RNAi approaches, complementing therapies (heme-pathway modulators), and potentially small-molecule or antibody-like strategies targeting upstream drivers of acute attacks.

Competitive analysis framework for investors

• Compare attack reduction magnitude, dosing frequency, lab monitoring intensity, and place-in-therapy.
• Evaluate payer fit:
  • drugs with easier monitoring or more predictable lab profiles tend to gain faster reimbursement acceptance.
• Track center adoption:
  • therapies that can be administered through existing infusion or specialty injection infrastructure show faster uptake.

(A precise competitor list requires current pipeline intel and patent/regulatory status, which is not provided here.)

---

What generic entry risks exist for GIVLAARI and how would challengers design around patents?

Answer: For an RNAi drug, “generic” entry risk is better framed as “alternative RNAi/biologic-like product” entry risk, and it hinges on patent design-around feasibility and regulatory comparability.

Typical design-around pathways

• Sequence changes to avoid claim language while maintaining ALAS1 knockdown.
• Delivery architecture changes to avoid conjugate/delivery claim coverage.
• Process changes to avoid manufacturing method claims.

Where the risk concentrates

• Claims tied to exact sequences are harder to design around without changing pharmacology.
• Claims tied to delivery chemistry can be harder if functional targeting is core to clinical effect.
• Manufacturing claims can be bypassed with different processes, but then comparability studies and regulatory requirements increase cost.

---

What patent litigation affects GIVLAARI: has it faced Paragraph IV equivalents, ITC actions, or settlement licensing?

Answer: Litigation risk is evaluated through:

• district court actions involving patent infringement,
• administrative proceedings (including ITC),
• settlement agreements that disclose entry “carve-outs” and timing.

(No litigation records are provided here, so a hard litigation timeline cannot be produced.)

---

What FDA pathway risks matter for GIVLAARI competitors: BLA vs 351(a) vs other routes?

Answer: Competitor regulatory risk depends on the closest approval pathway for an RNAi product and on how the FDA characterizes the product class. For investors, the critical issue is whether an alternative product can be approved with reduced clinical requirements.

Key regulatory factors

• Comparability framework: analytical similarity to givosiran’s siRNA and delivery system.
• Clinical bridge requirements: whether regulators demand new efficacy endpoints around AHP attack reduction.
• Safety signals: RNAi class risks (hepatic effects, off-target concerns) can extend development.

---

How does GIVLAARI compare with other AHP therapies on commercial readiness and patient value?

Answer: GIVLAARI’s commercial differentiator is typically its ability to reduce attack frequency with a regimen that is manageable for specialty care, which improves retention versus reactive-only therapies. Comparisons must be grounded in:

• trial endpoint performance (attack reduction rate),
• discontinuation reasons and tolerability,
• ease of monitoring and patient adherence.

(Comparative data and specific competitors are not provided here.)

---

Revenue exposure: what drives GIVLAARI financial sensitivity in the next 3 to 7 years?

Answer: The revenue model is most sensitive to (1) treated patient count growth, (2) persistence/retention, and (3) net price after contracting, plus (4) exclusion risks from payer formulary changes.

Model the three variables that typically move fastest

1. Patient adoption curve
   • new diagnosis capture,
   • referral center penetration,
   • time from diagnosis to treatment initiation.
2. Net pricing and contracting
   • rebates and managed care contracting,
   • prior authorization criteria stringency,
   • utilization management.
3. Safety and tolerability
   • discontinuations and dose modifications,
   • lab monitoring outcomes driving persistence.

Investment signal to watch

• Any indication of slowdown in the treated population growth rate or rising discontinuation would compress the revenue outlook more than a change in unit price alone.

---

What are the key R&D and partnering levers investors should track for GIVLAARI?

Answer: Investment upside typically comes from label expansion, new delivery strategies, and second-generation RNAi programs that share manufacturing and platform know-how, rather than from incremental chemistry within the same product.

Partnering pathways that matter

• Co-commercialization in AHP centers.
• Manufacturing and supply chain partnerships to de-risk scaling.
• Platform licenses if a sponsor seeks to monetize delivery chemistry or manufacturing IP.

---

Key Takeaways

• GIVLAARI’s investment case is built on AHP specialty adoption, payer contracting success, and retention, with IP and regulatory barriers shaping competitor timing more than classic small-molecule generic models.
• The largest de-risking event for a time horizon investor is mapping core composition and delivery claims to actual FDA-listed patent expiration dates and confirming whether later patents extend protection.
• Competitive entry risk for RNAi products is primarily design-around plus regulatory pathway and clinical comparability requirements, not ANDA-style equivalence.
• Revenue sensitivity is concentrated in patient treated volume and persistence, with net pricing and formulary friction acting as the main downside vectors.

---

FAQs

1) Is GIVLAARI eligible for generic substitution under U.S. law

No direct generic “substitution” pathway applies the way it does for standard small-molecule ANDAs; competitor products depend on their regulatory pathway characterization.

2) What makes an AHP RNAi competitor difficult to bring to market

Competitors must replicate both functional siRNA activity and the delivery system while meeting analytical similarity and clinical endpoint requirements.

3) How do payers usually decide whether to cover givosiran

Coverage decisions typically hinge on prior authorization criteria tied to diagnosis confirmation and clinical response proxies aligned with label endpoints.

4) What endpoints matter most for competitor comparability in AHP

Attack frequency reduction and safety monitoring patterns are the most commercially salient efficacy and tolerability anchors.

5) What investor milestones best signal reduced time-to-competition

Any publicly disclosed patent challenges, litigation schedules, or regulatory submissions that suggest a defined entry strategy and timeline.

---

References

1. U.S. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (GIVLAARI listing, search portal).
2. FDA labeling database (GIVLAARI prescribing information and regulatory history, search portal).
3. U.S. FDA. Drug Approval Reports and Approval Packages (givosiran, first approval documentation).